positive
Sudeep Pharma IPO Sees Rising GMP as Subscription Picks Up Momentum
Sudeep Pharma’s IPO continued to gain traction on its second subscription day, with the grey market premium (GMP) rising 5% since launch. The issue, which opened on November 21, was fully subscribed on Day 1 as investors bid for 1.50 crore shares against 1.05 crore on offer, reflecting 1.42 times subscription. As of early November 24, the GMP stood at ₹121, implying an estimated listing price of ₹714 versus the upper issue price of ₹593. This hints at a potential 20.40% listing gain.
Financially, the company reported revenue of ₹511.33 crore and a profit of ₹138.69 crore in FY25, showing steady YoY growth.
Companies:
- Sudeep Pharma Ltd.
Tags:
- ipo
- gmp
Explore:Mutual Fund AI Screening
positive
Sudeep Pharma IPO Sees Rising GMP as Subscription Picks Up Momentum
Sudeep Pharma’s IPO continued to gain traction on its second subscription day, with the grey market premium (GMP) rising 5% since launch. The issue, which opened on November 21, was fully subscribed on Day 1 as investors bid for 1.50 crore shares against 1.05 crore on offer, reflecting 1.42 times subscription. As of early November 24, the GMP stood at ₹121, implying an estimated listing price of ₹714 versus the upper issue price of ₹593. This hints at a potential 20.40% listing gain.
Financially, the company reported revenue of ₹511.33 crore and a profit of ₹138.69 crore in FY25, showing steady YoY growth.
Companies:
- Sudeep Pharma Ltd.
Tags:
- ipo
- gmp
Explore:Mutual Fund AI Screening
1 min read
102 words
Sudeep Pharma’s IPO gains momentum with higher GMP and strong early subscription, indicating a potential 20%+ listing upside based on grey market trends.
Sudeep Pharma’s IPO continued to gain traction on its second subscription day, with the grey market premium (GMP) rising 5% since launch. The issue, which opened on November 21, was fully subscribed on Day 1 as investors bid for 1.50 crore shares against 1.05 crore on offer, reflecting 1.42 times subscription. As of early November 24, the GMP stood at ₹121, implying an estimated listing price of ₹714 versus the upper issue price of ₹593. This hints at a potential 20.40% listing gain.
Financially, the company reported revenue of ₹511.33 crore and a profit of ₹138.69 crore in FY25, showing steady YoY growth.
Sudeep Pharma’s IPO continued to gain traction on its second subscription day, with the grey market premium (GMP) rising 5% since launch. The issue, which opened on November 21, was fully subscribed on Day 1 as investors bid for 1.50 crore shares against 1.05 crore on offer, reflecting 1.42 times subscription. As of early November 24, the GMP stood at ₹121, implying an estimated listing price of ₹714 versus the upper issue price of ₹593. This hints at a potential 20.40% listing gain.
Financially, the company reported revenue of ₹511.33 crore and a profit of ₹138.69 crore in FY25, showing steady YoY growth.
Companies:
- Sudeep Pharma Ltd.
Tags:
- ipo
- gmp
- ipo
- gmp
- markets
- sudeep pharma
- grey market premium